Market Currents
Mylan (MYL -0.6%) says its subsidiary, Mylan Pharmaceuticals, has received final FDA approval...
-
Wednesday, December 5, 2012, 11:22 AM ETMylan (MYL -0.6%) says its subsidiary, Mylan Pharmaceuticals, has received final FDA approval for its Abbreviated New Drug Application for Candesartan Cilexetil and Hydrochlorothiazide Tablets, the generic version of AstraZeneca's (AZN) Atacand HCT, which is indicated indicated for the treatment of hypertension. Mylan will begin shipping all approved strengths immediately.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
